RECOMMENDATIONS
Recommendation 1
7.20 The
committee recommends that the Government withdraw the statement made on
25 February 2011 regarding the deferral of the listing of new
medicines and the new rules applying to listings from that point forward.
Recommendation 2
7.21 The
committee recommends that the Government retract the statement that PBAC
listing recommendations will not be proceeded with until savings are found to
offset the costs of listing those medicines under the PBS.
Recommendation 3
7.22 The
committee recommends that the Government should explicitly state that it
rejects any implication that the listing of new medicines requires savings to
be made elsewhere in the health portfolio.
Recommendation 4
7.23 The
Government should restate its commitment to making an explicit decision
regarding the listing of new medicines on the PBS within the terms and intent
of the Memorandum of Understanding signed with Medicines Australia on
6 May 2010 and re-signed on 28 September 2010.
Recommendation 5
7.24 That
the Government reinstate the '$10 million rule' so that medicines that have a
financial impact of less than $10 million in each year over the forward
estimates can be listed on the PBS Schedule by the minister without waiting for
Cabinet approval.
Navigation: Previous Page | Contents | Next Page